XBIO — Xenetic Biosciences Income Statement
0.000.00%
Last trade - 00:00- $4.27m
- -$1.89m
- $2.50m
- 27
- 51
- 10
- 19
Annual income statement for Xenetic Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.437 | 1.16 | 1.71 | 2.54 | 2.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.4 | 6.91 | 8.42 | 7.06 | 6.7 |
| Operating Profit | -13.9 | -5.75 | -6.72 | -4.52 | -4.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.8 | -5.65 | -6.55 | -4.13 | -3.96 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.9 | -5.65 | -6.55 | -4.13 | -3.96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.9 | -5.65 | -6.55 | -4.13 | -3.96 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.9 | -5.65 | -6.55 | -4.13 | -3.96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.64 | -5.49 | -4.61 | -2.71 | -2.11 |